EIF4A2 and cancer: In triple-negative breast cancer, miR-5195-3p upregulation increases the sensitivity of cancer cells to paclitaxel; the silencing of eIF4A2 mimics this effect, and the restoration of eIF4A2 blocks this effect (Long et al., 2019).